Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorBase Therapeutics (Shanghai) Co., Ltd.
About this trial
This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer and colorectal cancer.NK510 will be administered by intravenous infusion for systemic therapy and intraperitoneal perfusion therapy. The safety and efficacy of this treatment will be evaluated.
Eligibility criteria
Qualifiers
Aged ≥ 18 years, regardless of gender.
Gastric cancer and colorectal cancer that are inoperable and unresectable with radiotherapy: For gastric cancer, molecular diagnosis confirms that it is not AFP-producing gastric cancer.
Progressive disease or recurrence after receiving ≥ 2 lines of treatment.
Drained ascites ≥ 500ml, or B-ultrasound/CT in the supine position shows ascites depth ≥ 3cm.
Disqualifiers
Pregnant or lactating women.
Subjects with central nervous system (CNS) metastases and/or carcinomatous meningitis with obvious symptoms.
A history of other malignant tumors within the past 3 years.
Subjects with active, known or suspected autoimmune diseases [excluding type 1 diabetes, hypothyroidism requiring only hormone replacement therapy, skin diseases that do not require systemic treatment (e.g., vitiligo, psoriasis, or alopecia), or diseases that are not expected to relapse without external triggers].
Trial design
Treatments tested in this trial
- NK510
- NK510
Treatment groups
15 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov